Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
ARX Stock Chart & Stats
AU$0.57
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.57
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$196.92M
Enterprise ValueAU$199.09M
Total Cash (Recent Filing)AU$20.71M
Total Debt (Recent Filing)AU$6.14M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 31, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding345,476,200
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)1.73
Price to Sales (P/S)1.90
P/FCF Ratio-25.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.16Price Target Upside103.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$98.95M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent double-digit revenue growth and a material year-over-year increase indicate expanding clinical adoption of Aroa's ECM products. Durable top-line expansion supports scale, improves operating leverage over time, and provides a larger base to absorb fixed costs and fund commercialization and R&D.
Robust Balance SheetAroa's high equity ratio and favorable debt metrics give it runway and financial flexibility to fund clinical programs, inventory and go-to-market activities without heavy leverage. Low financial risk strengthens resilience to reimbursement cycles and supports strategic investments over months.
Improving Profitability MetricsStrong gross margins and a shift to positive EBITDA in 2025 reflect improving unit economics and cost control. If sustained, these margin improvements enable durable operating leverage, better cash conversion as volumes grow, and reduced reliance on external capital to scale the business.
Bears Say
Persistent Net LossesOngoing net losses erode retained earnings and suppress return metrics, limiting internal funding capacity. Continued unprofitability increases the likelihood of future equity raises or other financing, which can dilute shareholders and constrain long-term return on equity improvement.
Negative Free Cash FlowSustained negative free cash flow hampers Aroa's ability to self-fund capex, inventory and commercialization investments. Even with improving operations, negative FCF raises financing needs and execution risk when scaling, potentially slowing the path to durable cash generation.
Channel And Procedure DependenceRevenue reliance on procedure volumes and distributor channels exposes Aroa to reimbursement shifts, provider purchasing cycles and potential customer concentration. Adoption and growth hinge on sustained clinical utilization and partner execution, adding structural adoption risk over coming months.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.35 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$196.92M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s upcoming earnings report date is May 31, 2026 which is in 65 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on Nov 25, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of AU$0.01 by -AU$0.013.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is <0.01.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,476,200 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of AU$0.01. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.16 (103.51% Upside)
AU$1.16 (103.51% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-3.80%
Trailing 12-Months
Asset Growth
-1.71%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$1.16
▲(103.51% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---